Pentraxin-3 as a Biomarker in Diabetes Mellitus: Insights into Inflammation, Vascular Complications, and Modulation by Antidiabetic Medications DOI Creative Commons

Roxana-Cristina Dobriceanu,

Andreea-Daniela Meca, Ianis Kevyn Stefan Boboc

et al.

Biomedicines, Journal Year: 2025, Volume and Issue: 13(4), P. 891 - 891

Published: April 7, 2025

Diabetes mellitus (DM) is a multifactorial metabolic disorder associated with systemic inflammation and vascular complications. Pentraxin-3 (PTX3) has emerged as key biomarker of endothelial dysfunction in DM. We aimed to examine the role PTX3 DM assesses impact pharmacological interventions on its expression. The review included studies analyzing modulation by antidiabetic therapies, such sodium-glucose cotransporter-2 inhibitors (SGLT-2i), glucagon-like peptide-1 agonists (GLP-1a), dipeptidyl peptidase-4 (DPP-4i), well effects lifestyle interventions. Clinical experimental demonstrated strong correlation between levels progression. Elevated were diabetic complications, including nephropathy, retinopathy, cardiovascular diseases. Antidiabetic drugs showed differential expression, GLP-1a DPP-4i significantly reducing levels, while SGLT-2i displayed paradoxical increase. Lifestyle interventions, dietary modifications weight loss, yielded inconsistent effects, suggesting genetic factors influence regulation. While particularly DPP-4i, demonstrate anti-inflammatory further research needed standardize measurement explore potential therapeutic target. Personalized treatment strategies incorporating profiling may optimize control disease management patients.

Language: Английский

Targeting Liposome-Driven Inflammation in Gestational Diabetes Mellitus: Insights from Multiomics and Molecular Docking DOI

Yanyan Hu,

Dan Wang, Jizheng Wang

et al.

Published: Jan. 1, 2025

Language: Английский

Citations

0
Pentraxin-3 as a Biomarker in Diabetes Mellitus: Insights into Inflammation, Vascular Complications, and Modulation by Antidiabetic Medications DOI Creative Commons

Roxana-Cristina Dobriceanu,

Andreea-Daniela Meca, Ianis Kevyn Stefan Boboc

et al.

Biomedicines, Journal Year: 2025, Volume and Issue: 13(4), P. 891 - 891

Published: April 7, 2025

Diabetes mellitus (DM) is a multifactorial metabolic disorder associated with systemic inflammation and vascular complications. Pentraxin-3 (PTX3) has emerged as key biomarker of endothelial dysfunction in DM. We aimed to examine the role PTX3 DM assesses impact pharmacological interventions on its expression. The review included studies analyzing modulation by antidiabetic therapies, such sodium-glucose cotransporter-2 inhibitors (SGLT-2i), glucagon-like peptide-1 agonists (GLP-1a), dipeptidyl peptidase-4 (DPP-4i), well effects lifestyle interventions. Clinical experimental demonstrated strong correlation between levels progression. Elevated were diabetic complications, including nephropathy, retinopathy, cardiovascular diseases. Antidiabetic drugs showed differential expression, GLP-1a DPP-4i significantly reducing levels, while SGLT-2i displayed paradoxical increase. Lifestyle interventions, dietary modifications weight loss, yielded inconsistent effects, suggesting genetic factors influence regulation. While particularly DPP-4i, demonstrate anti-inflammatory further research needed standardize measurement explore potential therapeutic target. Personalized treatment strategies incorporating profiling may optimize control disease management patients.

Language: Английский

Citations

0